Cobimetinib racemate

• CAT Number: I005552
• CAS Number: 934662-91-6
• Molecular Formula: C21H21F3IN3O2
• Molecular Weight: 531.31
• Purity: ≥95%
• Synonyms: GDC-0973;XL518
• Target: MEK
• Solubility: DMSO: ≥ 40 mg/mL
• Storage: Store at -20°C
• IUPAC Name: [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-(3-hydroxy-3-piperidin-2-ylazetidin-1-yl)methanone
• InChI: InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2
• InChIKey: BSMCAPRUBJMWDF-UHFFFAOYSA-N
• SMILES: C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O

Cobimetinib racemate(CAT: I005552) is a mixture of stereoisomers of Cobimetinib, a potent inhibitor of MEK1 and MEK2, key components of the MAPK/ERK signaling pathway. By inhibiting these kinases, it disrupts abnormal cell proliferation and survival signals commonly associated with various cancers, particularly those driven by mutations in the RAS-RAF-MEK-ERK pathway. Cobimetinib racemate is widely used in preclinical research to explore the therapeutic potential of MEK inhibition in oncology, as well as to study pathway-specific cellular mechanisms. Its high quality and consistency make it an essential tool for advancing drug discovery and cancer biology research.